| As Of | Filing | | Doc. | | Page | | Title | Docs. |
|---|
| | |  |
| 7/20/23 | | 424B5 | | | | 1 | | About the Company | 2 |
| | | | | | 1 | | About This Prospectus | 2 |
| | | | | | 1 | | About This Prospectus Supplement | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Additional Information | 1 |
| | | | | | 1 | | Agreements with Our Senior Management | 1 |
| | | | | | 1 | | American Depositary Shares | 1 |
| | | | | | 1 | | Attendance Record Board of Director Meetings | 1 |
| | | | | | 1 | | Audit Committee Financial Expert | 1 |
| | | | | | 1 | | Board Practices | 1 |
| | | | | | 1 | | Business Overview | 1 |
| | | | | | 1 | | Business Overview-Collaboration Agreements | 1 |
| | | | | | 1 | | Business Overview-License Agreements | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Capitalization | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Capitalization and Indebtedness | 1 |
| | | | | | 1 | | Cash Flows -- Operating and Capital Expenditure Requirements | 1 |
| | | | | | 1 | | Cautionary Statement Regarding Forward-Looking Statements | 3 |
| | | | | | 1 | | Cautionary Statement with Respect to Forward-Looking Statements | 1 |
| | | | | | 1 | | Change in Registrant's Certifying Accountant | 1 |
| | | | | | 1 | | Code of Ethics | 1 |
| | | | | | 1 | | Compensation | 1 |
| | | | | | 1 | | Consolidated Statements and Other Financial Information | 1 |
| | | | | | 1 | | Consolidated Statements of Cash Flows | 1 |
| | | | | | 1 | | Consolidated Statements of Changes in Equity | 1 |
| | | | | | 1 | | Consolidated Statements of Comprehensive Income (Loss) | 1 |
| | | | | | 1 | | Consolidated Statements of Financial Position | 1 |
| | | | | | 1 | | Consolidated Statements of Profit or Loss | 1 |
| | | | | | 1 | | Controls and Procedures | 1 |
| | | | | | 1 | | Corporate Governance | 1 |
| | | | | | 1 | | Critical Accounting Estimates | 1 |
| | | | | | 1 | | Current | 1 |
| | | | | | 1 | | Cybersecurity | 1 |
| | | | | | 1 | | Debt Securities | 1 |
| | | | | | 1 | | Defaults, Dividend Arrearages and Delinquencies | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Description of American Depositary Shares | 2 |
| | | | | | 1 | | Description of Securities | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Description of Securities Other Than Equity Securities | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Description of Share Capital | 2 |
| | | | | | 1 | | Description of Share Capital and Articles of Association | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Dilution | 3 |
| | | | | | 1 | | Directors and Senior Management | 1 |
| | | | | | 1 | | Directors, Senior Management and Employees | 1 |
| | | | | | 1 | | Disclosure of A Registrant's Action to Recover Erroneously Awarded Compensation | 1 |
| | | | | | 1 | | Disclosure Regarding Foreign Jurisdictions That Prevent Inspections | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Dividend Policy | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Dividends and Paying Agents | 1 |
| | | | | | 1 | | Documents on Display | 1 |
| | | | | | 1 | | Employees | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Enforceability of Certain Civil Liabilities | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Exchange Controls | 1 |
| | | | | | 1 | | Exemptions From the Listing Standards for Audit Committees | 1 |
| | | | | | 1 | | Exhibit 2.3-Change in the Capital | 1 |
| | | | | | 1 | | Exhibit 2.3-Comparison of Dutch Corporate Law, our Articles of Association and Board of Directors By-Laws and DGCL | 1 |
| | | | | | 1 | | Exhibit 2.3-Limitations on the Right to Own Securities | 1 |
| | | | | | 1 | | Exhibits | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Expenses | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Expenses of the Issue | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Experts | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Financial Information | 1 |
| | | | | | 1 | | Financial risk management | 1 |
| | | | | | 1 | | Financial Statements | 1 |
| | | | | | 1 | | Foreign exchange risk | 1 |
| | | | | | 1 | | Formulations | 1 |
| | | | | | 1 | | Global geo- and socio-political threats and macro-economic uncertainty and other unforeseen political crises could materially and adversely affect our business and financial performance | 1 |
| | | | | | 1 | | Healthcare Law and Regulation | 1 |
| | | | | | 1 | | History and Development of the Company | 1 |
| | | | | | 1 | | Identity of Directors, Senior Management and Advisers | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Incorporation by Reference | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Information on the Company | 1 |
| | | | | | 1 | | Insider Trading Policies | 1 |
| | | | | | 1 | | Intangible assets | 1 |
| | | | | | 1 | | Intellectual Property | 1 |
| | | | | | 1 | | Interests of Experts and Counsel | 1 |
| | | | | | 1 | | Item 1 | 1 |
| | | | | | 1 | | Item 10 | 1 |
| | | | | | 1 | | Item 11 | 1 |
| | | | | | 1 | | Item 12 | 1 |
| | | | | | 1 | | Item 13 | 1 |
| | | | | | 1 | | Item 14 | 1 |
| | | | | | 1 | | Item 15 | 1 |
| | | | | | 1 | | Item 16 | 1 |
| | | | | | 1 | | Item 16A | 1 |
| | | | | | 1 | | Item 16B | 1 |
| | | | | | 1 | | Item 16C | 1 |
| | | | | | 1 | | Item 16D | 1 |
| | | | | | 1 | | Item 16E | 1 |
| | | | | | 1 | | Item 16F | 1 |
| | | | | | 1 | | Item 16G | 1 |
| | | | | | 1 | | Item 16H | 1 |
| | | | | | 1 | | Item 16I | 1 |
| | | | | | 1 | | Item 16J | 1 |
| | | | | | 1 | | Item 16K | 1 |
| | | | | | 1 | | Item 17 | 1 |
| | | | | | 1 | | Item 18 | 1 |
| | | | | | 1 | | Item 19 | 1 |
| | | | | | 1 | | Item 2 | 1 |
| | | | | | 1 | | Item 3 | 1 |
| | | | | | 1 | | Item 4 | 1 |
| | | | | | 1 | | Item 4A | 1 |
| | | | | | 1 | | Item 5 | 1 |
| | | | | | 1 | | Item 6 | 1 |
| | | | | | 1 | | Item 7 | 1 |
| | | | | | 1 | | Item 8 | 1 |
| | | | | | 1 | | Item 9 | 1 |
| | | | | | 1 | | Key Information | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Legal Matters | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Licensure and Regulation of Biologics in the U.S | 1 |
| | | | | | 1 | | Liquidity and Capital Resources | 1 |
| | | | | | 1 | | Liquidity and Capital Resources -- Cash Flows -- Operating and Capital Expenditure Requirements | 1 |
| | | | | | 1 | | Major Shareholders | 1 |
| | | | | | 1 | | Major Shareholders and Related Party Transactions | 1 |
| | | | | | 1 | | Markets | 1 |
| | | | | | 1 | | Material Belgian Tax Consequences | 1 |
| | | | | | 1 | | Material Contracts | 1 |
| | | | | | 1 | | Material Modifications to the Rights of Security Holders and Use of Proceeds | 1 |
| | | | | | 1 | | Memorandum and Articles of Association | 1 |
| | | | | | 1 | | Mine Safety Disclosure | 1 |
| | | | | | 1 | | Note 10-Financial assets -- current | 1 |
| | | | | | 1 | | Note 11-Cash and cash equivalents | 1 |
| | | | | | 1 | | Note 13 -Share-based payments | 1 |
| | | | | | 1 | | Note 15-Product net sales | 1 |
| | | | | | 1 | | Note 18-Segment reporting | 1 |
| | | | | | 1 | | Note 2.17 -Product net sales | 1 |
| | | | | | 1 | | Note 22-Leases | 1 |
| | | | | | 1 | | Note 24-Income taxes | 1 |
| | | | | | 1 | | Note 26 for more information on the financial risk management | 1 |
| | | | | | 1 | | Note 26-Financial risk management | 1 |
| | | | | | 1 | | Note 29-Commitments | 1 |
| | | | | | 1 | | Note 32-Events after the balance sheet date | 1 |
| | | | | | 1 | | Note 4 -- Property, plant and equipment | 1 |
| | | | | | 1 | | Note 5 -- Intangible assets | 1 |
| | | | | | 1 | | Notes to the Consolidated Financial Statements | 1 |
| | | | | | 1 | | Offer and Listing Details | 1 |
| | | | | | 1 | | Offer and Listing, The | 1 |
| | | | | | 1 | | Offer Statistics and Expected Timetable | 1 |
| | | | | | 1 | | Operating and Capital Expenditure Requirements | 1 |
| | | | | | 1 | | Operating and Financial Review and Prospects | 1 |
| | | | | | 1 | | Operating Results | 1 |
| | | | | | 1 | | Organizational Structure | 1 |
| | | | | | 1 | | Other Securities | 1 |
| | | | | | 1 | | Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems | 1 |
| | | | | | 1 | | Our Exclusive License with Elektrofi for efgartigimod | 1 |
| | | | | | 1 | | Our Exclusive License with Halozyme for ENHANZE(R) | 1 |
| | | | | | 1 | | Our Internal Programs | 1 |
| | | | | | 1 | | Our Partnered Programs | 1 |
| | | | | | 1 | | Part I | 1 |
| | | | | | 1 | | Part Ii | 1 |
| | | | | | 1 | | Part Iii | 1 |
| | | | | | 1 | | Passive Foreign Investment Company Considerations | 1 |
| | | | | | 1 | | Plan of Distribution | 3 |
| | | | | | 1 | | Platform Technologies | 1 |
| 9/27/23 | | S-8 | | | | 1 | | Power of Attorney (included on the signature page) | 1 |
| 3/21/24 | | 20-F | | | | 1 | | Principal Accountant Fees and Services | 1 |
| | | | | | 1 | | Property, plant and equipment | 1 |
| | | | | | 1 | | Property, Plants and Equipment | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Prospectus Supplement Summary | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Purchases of Equity Securities by the Issuer and Affiliated Purchasers | 1 |
| | | | | | 1 | | Quantitative and Qualitative Disclosures About Market Risk | 1 |
| | | | | | 1 | | Reasons for the Offer and Use of Proceeds | 1 |
| | | | | | 1 | | Regulation | 1 |
| | | | | | 1 | | Related Party Transactions | 1 |
| | | | | | 1 | | Remuneration | 1 |
| | | | | | 1 | | Report Audit and Compliance Committee | 1 |
| | | | | | 1 | | Reports of Independent Registered Public Accounting Firm | 1 |
| | | | | | 1 | | Research and Development, Patents and Licenses | 1 |
| | | | | | 1 | | Reserved | 1 |
| | | | | | 1 | | Risk Factors | 3 |
| | | | | | 1 | | Risk Factors Related to argenx's Business and Industry | 1 |
| | | | | | 1 | | Risk Factors Related to argenx's Financial Position and Need for Additional Capital | 1 |
| | | | | | 1 | | Risk Factors Related to argenx's Organization and Operations | 1 |
| | | | | | 1 | | Risk Factors Related to Commercialization of argenx's Products and Product Candidates, Including for New Indications | 1 |
| | | | | | 1 | | Risk Factors Related to Other Government Regulations | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | S-1 | 2 |
| | | | | | 1 | | S-12 | 2 |
| | | | | | 1 | | S-15 | 2 |
| | | | | | 1 | | S-16 | 2 |
| | | | | | 1 | | S-17 | 2 |
| | | | | | 1 | | S-18 | 2 |
| | | | | | 1 | | S-19 | 2 |
| | | | | | 1 | | S-27 | 2 |
| | | | | | 1 | | S-3 | 2 |
| | | | | | 1 | | S-47 | 2 |
| | | | | | 1 | | S-5 | 2 |
| | | | | | 1 | | S-61 | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Say-On-Pay and Proposed Amendments to the Remuneration Policy | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Selling Securityholders | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Selling Shareholders | 1 |
| | | | | | 1 | | Share Capital | 1 |
| | | | | | 1 | | Share Ownership | 1 |
| | | | | | 1 | | Significant Changes | 1 |
| | | | | | 1 | | Statement by Experts | 1 |
| | | | | | 1 | | Subsidiary Information | 1 |
| | | | | | 1 | | Table of Contents | 3 |
| | | | | | 1 | | Taxation | 3 |
| | | | | | 1 | | Taxation -- Material Belgian Tax Consequences | 1 |
| | | | | | 1 | | Taxation -Certain Material U.S. Federal Income Tax Considerations for U.S. Holders | 1 |
| | | | | | 1 | | The Offer and Listing | 1 |
| | | | | | 1 | | Trend Information | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Underwriting | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Unresolved Staff Comments | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Use of Proceeds | 2 |
| 3/21/24 | | 20-F | | | | 1 | | Warrants and Rights | 1 |
| | | | | | 1 | | We face risks related to natural disasters and public health issues, that could negatively affect our business and financial condition | 1 |
| | | | | | 1 | | We face significant competition for our drug discovery and development efforts | 1 |
| 7/20/23 | | 424B5 | | | | 1 | | Where You Can Find More Information | 2 |
| 3/21/24 | | 20-F | | | | 1 | | 10.A | 1 |
| | | | | | 1 | | 10.B | 1 |
| | | | | | 1 | | 10.C | 1 |
| | | | | | 1 | | 10.D | 1 |
| | | | | | 1 | | 10.E | 1 |
| | | | | | 1 | | 10.F | 1 |
| | | | | | 1 | | 10.G | 1 |
| | | | | | 1 | | 10.H | 1 |
| | | | | | 1 | | 10.I | 1 |
| | | | | | 1 | | 12.A | 1 |
| | | | | | 1 | | 12.B | 1 |
| | | | | | 1 | | 12.C | 1 |
| | | | | | 1 | | 12.D | 1 |
| 9/27/23 | | S-8 | | | | 1 | | 24.1 | 1 |
| 3/21/24 | | 20-F | | | | 1 | | 3.A | 1 |
| | | | | | 1 | | 3.B | 1 |
| | | | | | 1 | | 3.C | 1 |
| | | | | | 1 | | 3.D | 1 |
| | | | | | 1 | | 4.A | 1 |
| | | | | | 1 | | 4.B | 1 |
| | | | | | 1 | | 4.C | 1 |
| | | | | | 1 | | 4.D | 1 |
| | | | | | 1 | | 5.A | 1 |
| | | | | | 1 | | 5.B | 1 |
| | | | | | 1 | | 5.C | 1 |
| | | | | | 1 | | 5.D | 1 |
| | | | | | 1 | | 5.E | 1 |
| | | | | | 1 | | 6.A | 1 |
| | | | | | 1 | | 6.B | 1 |
| | | | | | 1 | | 6.C | 1 |
| | | | | | 1 | | 6.D | 1 |
| | | | | | 1 | | 6.E | 1 |
| | | | | | 1 | | 6.F | 1 |
| | | | | | 1 | | 7.A | 1 |
| | | | | | 1 | | 7.B | 1 |
| | | | | | 1 | | 7.C | 1 |
| | | | | | 1 | | 8.A | 1 |
| | | | | | 1 | | 8.B | 1 |
| | | | | | 1 | | 9.A | 1 |
| | | | | | 1 | | 9.B | 1 |
| | | | | | 1 | | 9.C | 1 |
| | | | | | 1 | | 9.D | 1 |
| | | | | | 1 | | 9.E | 1 |
| | | | | | 1 | | 9.F | 1 |
